Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

MannKind’s Inhaled Insulin Trials Meet Their Goals

By Pharmaceutical Processing | December 5, 2008

Drug developer MannKind Corp. said Thursday its fast-acting inhaled insulin Afresa met its goals in two clinical trials, as the drug was more effective in lowering blood sugar than other drugs and did not cause lung damage. Both late stage trials met their goals, the company said. The first showed that a combination of Afresa and long-acting insulin lowered blood sugar levels more than a premixed twice-per-day insulin injection. In the second trial, the company said no adverse effects on the lungs were observed. MannKind said it plans to request Food and Drug Administration approval of Afresa in early 2009. It will report full results from the two trials, called study 102 and study 030, in mid-December. More than 2,000 type 1 and type 2 diabetes patients were involved in the trials. Afresa is a powdered insulin that is designed to be inhaled and dissolve immediately on contact with the lungs, allowing the body to reach peak levels within 12 to 14 minutes. That’s similar to the way insulin is released in people without diabetes, MannKind said. By contrast, the company said injected insulin can take up to an hour to reach peak levels, and they can also take longer to return to normal levels. MannKind is developing drugs that can be inhaled and absorbed more easily with a technology called Technosphere.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE